Atlas Trials

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Clinical trial NCT06984718 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06984718
Sponsor
Akeso
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HCCHepatocellular Carcinoma
Start date
2025-06-25
Primary completion
2026-11-30
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.